Antibody Information

General Information of This Antibody

Each Antibody-drug Conjugate Related to This Antibody

Full Information of The Activity Data of The ADC(s) Related to This Antibody

Anti-GPC3 ADC [Investigative]

ADC Info

Discovered Using Patient-derived Xenograft Model

Click To Hide/Show 3 Activity Data Related to This Level

Experiment 1 Reporting the Activity Date of This ADC				[1]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 98.00% (Day 42)	High GPC1 expression(GPC1+++)
Method Description	Mice were treated with isotype control CD 70 antibody drug conjugate (ADC) or antiglypican 3 ADC at 0.75 mg/kg on Q7D4 schedule or at 5 mg/kg on QD1 schedule.
In Vivo Model	Hepatocellular carcinoma PDX model (PDX: LI1097)
Experiment 2 Reporting the Activity Date of This ADC				[1]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 100.00% (Day 100)	High GPC1 expression(GPC1+++)
Method Description	Mice were treated with isotype control CD 70 antibody drug conjugate (ADC) or antiglypican 3 ADC at 0.75 mg/kg on Q7D4 schedule or at 5 mg/kg on QD1 schedule.
In Vivo Model	Hepatocellular carcinoma PDX model (PDX: LI1068)
Experiment 3 Reporting the Activity Date of This ADC				[1]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 100.00% (Day 53)	High GPC1 expression(GPC1+++)
Method Description	Mice were treated with isotype control CD 70 antibody drug conjugate (ADC) or antiglypican 3 ADC at 0.75 mg/kg on Q7D4 schedule or at 5 mg/kg on QD1 schedule.
In Vivo Model	Hepatocellular carcinoma PDX model (PDX: LI1037)

References

Ref 1	A novel semi-mechanistic tumor growth fraction model for translation of preclinical efficacy of anti-glypican 3 antibody drug conjugate to human. Biopharm Drug Dispos. 2020 Nov;41(8-9):319-333. doi: 10.1002/bdd.2249. Epub 2020 Aug 19.